Pediatric brain tumors: Mutations of two dioxygenases (hABH2 and hABH3) that directly repair alkylation damage

Valentina Cetica, Lorenzo Genitori, Laura Giunti, Massimiliano Sanzo, Gabriella Bernini, Maura Massimino, Iacopo Sardi

Research output: Contribution to journalArticlepeer-review


Alkylating agents, commonly used for brain tumor therapy, induce DNA and RNA lesions that, if not repaired, drive cells to apoptosis. Thus, cellular mechanisms that are responsible for nucleic acid repair are possibly involved in drug resistance. This work analyzes hABH2 and hABH3, two human Fe(II)-dependent dioxygenases in pediatric brain tumors that are treated with alkylating agents. We analyzed 25 brain tumor samples for hABH2 and hABH3 mutations; a subset of samples was tested for quantitative expression with Real-Time PCR. Sequencing analysis showed two new mutations in two glioma patients, one of hABH2 coding sequence (I141 V) and the other of hABH3 (D189 N). The mutation at codon 189 falls in a crucial region of the protein. All subjects analyzed by Real-Time PCR showed an enhanced expression of the two genes, particularly of hABH2. This is the first study of hABH2 and hABH3 in pediatric brain tumors; further molecular investigations of their mutations and expression may help determine their role in response to chemotherapy.

Original languageEnglish
Pages (from-to)195-201
Number of pages7
JournalJournal of Neuro-Oncology
Issue number2
Publication statusPublished - 2009


  • Brain/central nervous system cancers
  • DNA damage
  • Drug resistance
  • Pediatric cancers
  • Repair mechanisms

ASJC Scopus subject areas

  • Cancer Research
  • Clinical Neurology
  • Oncology
  • Neurology


Dive into the research topics of 'Pediatric brain tumors: Mutations of two dioxygenases (hABH2 and hABH3) that directly repair alkylation damage'. Together they form a unique fingerprint.

Cite this